Parecer de pré-exame
#6.23
06/23/2026
RPI 2894
Application data
Number
112023010340Type
Filing
Publication
PCT
EP2021084254 The INPI issued a technical opinion on patentability. The applicant must respond for examination to continue.
Latest action published by the INPI: 06/23/2026. We update with every new RPI gazette, published weekly.
Applicants
DELTA 4 GMBH
AT
Inventors
P. P. (pessoa física)
AT
IPC Classification
Priority claims
EP
20211662.0 · 12/03/2020
Abstract
PREPARAÇÃO FARMACÊUTICA QUE COMPREENDE SAROGLITAZAR E ÁCIDO MIRÍSTICO PARA USO NO TRATAMENTO DE GLOMERULOESCLEROSE SEGMENTAR FOCAL (GESF). A presente invenção refere-se a uma preparação farmacêutica que compreende saroglitazar e ácido mirístico, ou um de seus sais ou solvatos, para uso no tratamento de glomeruloesclerose segmentar focal (GESF).
Publications in the Brazilian Industrial Property Gazette (RPI).
#6.23
06/23/2026
RPI 2894
#1.3
06/27/2023
RPI 2738
#1.1
06/06/2023
RPI 2735
From the same holder
Same category
Patent monitoring
Receive alerts on INPI events, decisions, and expiry dates for your portfolio.